Nanologica AB (publ)

Hi, my name is Andreas Dagman. I am the CEO and one of the largest owners of Nanologica. I have been able to present the report for the third quarter. Before I do that, I'll just briefly say a little bit about our vision. Better and cheaper medicine through poor silica. And just to make drugs cheaper, that's what we're working on. And I'm going to talk a little bit about how we make diabetes drugs cheaper. A little bit about the highlights in the quarter. Vi har fått flera ordrar och det är vi väldigt nöjda med på vår produkt Endlabsaga. Vår första storskaliga batch är klar och vi har faktiskt gjort flera nu. Vi genomförde en företrädesermination som gick väldigt bra. Vi utökade dessutom ledningsgruppen med Katarina Ahlernäs som leder vårt arbete inom kromatografi. Så till siffrorna. Blygsam försäljning 410 000. And a turnover result of minus 9.6 million, which is then compared with a little over 11 million in the previous quarter, or the corresponding quarter last year. And if you also look at the corresponding figures last quarter, they are also significantly higher. A little lower, or better, we can say, turnover result. During the period, we had 8.6 million in the cash register, but since then we have carried out a pre-trial submission where we have hardly been delivered. 80 million kronor. And we did the pre-evaluation now during the fall. We did it almost completely ourselves and we did it without a discount and it went very well. Almost all of the major owners stood up on the company and signed their share. And then we had the largest owner, Fly Invest, who chose to guarantee a very cheap penny. It also made the costs very low for this emission, together with the fact that we did not do it with a discount, so the courses have not been put together as standard with many other companies. So we are very happy about that. This means that we can then invest primarily in chromatography, both on the production, sales and application side. We have received several orders, but before I talk more specifically about orders, I would like to say something about demand. The demand for our type of products is actually completely unaffected by the worry we see in the world. Energy prices, conjecture with several, it does not affect the underlying growth that exists in the market. And we still have very favorable market conditions. There is a great interest in our products on the market. And it actually depends on three different factors. There are a number of potential blockbusters that are about to be launched or about to be rolled out that need our type of technology to be able to be produced. Then we have that the number of diabetics has actually increased in the world after Covid and the need for insulin, which also requires our type of technology, has increased. And we also see quite clearly this migration, which is significantly slower but very steady, where we have from a shift from small molecules to peptides. And small molecules do not need our type of technology when they are cleaned, while almost all peptides need it. And that also makes it a very good underlying driving force in the market. And then we have taken a number of orders, we are working with one of the world's largest insulin producers who want to have a full-scale test. And then we have Yunbo, who is our Chinese partner, they will have made the first order. And then we have a customer from the American market, and we probably would have had more orders if we had been much further ahead in production. And when you talk about that, we have large-scale production in a large facility where we have produced the first large-scale batch and actually the second and almost the third as well. I would have wished that we had been able to deliver to customers already. We have not been able to do that, and that has to do with the fact that we have a very strong focus on quality. And sometimes it doesn't go as fast as you want. Men det går stadigt framåt och det är jag väldigt nöjd över. Det läggs ner väldigt mycket energi på det. Och i och med företrädelseemissionen så har vi också möjlighet att investera och optimera de här processerna i produktion. Och vi jobbar väldigt hårt med det och jag kommer prata om det lite grann framöver också. Vi har ju ett läkemedelsområde som jag inte brukar prata så mycket om. Och det har ju att göra med att vi har mycket intern utveckling där vi förväntar oss inte speciellt mycket nyheter under de närmaste månaderna eller kvartalen. But what we do is that we develop particles for inhalation. And then it is so easy and so difficult to develop particles that can both carry different types of drugs and that can be resolved quite quickly in the lungs and not cause irritation. We are going to do a safety study on that later, and there is a great interest for our products, but we have to deliver some data before that, and that means that we do not expect much of this area in the next quarter. What will happen in the next quarter? We will deliver products to customers in preparatory chromatography. under Q4 already, and then it became a violent focus on production, production, production, to be able to deliver the orders we have and to be able to take new orders, as I mentioned earlier, so we would have taken significantly more if we had had products on the shelves. So we work very, very hard with that and will continue to work in the foreseeable future, with a very strong focus on production. And then we hope that in 2023 we can choose a medical candidate for clinical development within our other business area. The next conclusion will be in mid-February. And if you have any questions, please feel free to contact us. And that was all from me here at Nanologica. Andreas Bergman is my name and have a nice day. Thank you for listening.